Rivaroxaban prevents the development of chronic thromboembolic pulmonary hypertension in mice- Novel beneficial effects of the FXa inhibitor-

Back

ESC Premium Access

Rivaroxaban prevents the development of chronic thromboembolic pulmonary hypertension in mice- Novel beneficial effects of the FXa inhibitor-

Session: What is new in venous thromboembolism?

Topic: Treatment of hypertension

Speaker: Mr M. Al-Mamun (Sendai, JP)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Mr Md Elias Al-Mamun

Tohoku University Graduate School of Medicine, Sendai (Japan)

0 follower

6 more presentations in this session

Long-term effects of unprovoked venous thromboembolism on mortality and major cardiovascular events

Speaker: Doctor W. Chang (Tainan, TW)

Access

Abstract

Slides

Comparative safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism - a Danish nationwide study

Speaker: Ms C. Clausen (Hellerup, DK)

Access

Abstract

Validation of the prognostic impact of copeptin in normotensive pulmonary embolism in a european multicentre study.

Speaker: Doctor K. Hellenkamp (Goettingen, DE)

Access

Abstract

Slides

A novel experimental in vivo model of acute pulmonary embolism

Speaker: Doctor J. Schultz (Aarhus, DK)

Access

Abstract

Slides

The YEARS algorithm for suspected pulmonary embolism leads to much shorter diagnostic turnaround time than conventional algorithms

Speaker: Doctor E. Klok (Leiden, NL)

Access

Abstract

Slides

Access the full session

What is new in venous thromboembolism?

Speakers: Mr M. Al-Mamun, Doctor W. Chang, Ms C. Clausen, Doctor K. Hellenkamp, Doctor J. Schultz...

Access

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources